Raymond James Financial
CCCC icon

Raymond James Financial’s C4 Therapeutics CCCC Stock Holding History

Raymond James Financial’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.4K Buy
+11,860
New +$40.6K ﹤0.01% 5247
2025
Q3 		– Sell
-135
Closed -$193 – 5256
2025
Q2 		$193 Buy
+135
New +$196 ﹤0.01% 6787

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial's CCCC Position: Q2 2026 in Review

Raymond James Financial opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 11,860 shares worth $55.4K. The stake represents ﹤0.01% of the portfolio and ranks #5247 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in CCCC as recently as Q2 2025.

Raymond James Financial first reported a position in CCCC in Q2 2025 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Raymond James Financial held 11,860 shares of C4 Therapeutics worth $55.4K as of Q2 2026.
  • C4 Therapeutics was a new Raymond James Financial position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5247 holding.
  • Raymond James Financial first reported a position in C4 Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.